| Literature DB >> 31717621 |
Radu Albulescu1,2, Adrian-Claudiu Popa3,4, Ana-Maria Enciu1,5, Lucian Albulescu1, Maria Dudau1,5, Ionela Daniela Popescu1, Simona Mihai1, Elena Codrici1, Sevinci Pop1, Andreea-Roxana Lupu1,6, George E Stan3, Gina Manda1, Cristiana Tanase1,7.
Abstract
Recently, a large spectrum of biomaterials emerged, with emphasis on various pure, blended, or doped calcium phosphates (CaPs). Although basic cytocompatibility testing protocols are referred by International Organization for Standardization (ISO) 10993 (parts 1-22), rigorous in vitro testing using cutting-edge technologies should be carried out in order to fully understand the behavior of various biomaterials (whether in bulk or low-dimensional object form) and to better gauge their outcome when implanted. In this review, current molecular techniques are assessed for the in-depth characterization of angiogenic potential, osteogenic capability, and the modulation of oxidative stress and inflammation properties of CaPs and their cation- and/or anion-substituted derivatives. Using such techniques, mechanisms of action of these compounds can be deciphered, highlighting the signaling pathway activation, cross-talk, and modulation by microRNA expression, which in turn can safely pave the road toward a better filtering of the truly functional, application-ready innovative therapeutic bioceramic-based solutions.Entities:
Keywords: angiogenesis; bioceramics; hydroxyapatite; in vitro testing; microRNA; osteogenesis; signaling pathways
Year: 2019 PMID: 31717621 PMCID: PMC6888321 DOI: 10.3390/ma12223704
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Workflow for selection of calcium phosphate (CaP)-based bioceramics suitable for patient applications. The left diagram is a general workflow diagram, from material synthesis to clinical application. In vitro testing is detailed in the right panel.
Cellular viability and cytotoxicity tests. CaP—calcium phosphate; HA—hydroxyapatite; MTS—3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTT—3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; LDH—lactate dehydrogenase.
| Type of CaP | Type of Cells | Methodological Approach | Main Effects | References |
|---|---|---|---|---|
| Cell Viability | ||||
| HA nanoparticles produced via wet chemical synthesis (37 °C) and hydrothermal synthesis (180 °C) | MG63 osteoblast-like cells | MTS cell proliferation assay | Neither particle, in doses lower than 0.5 mg/mL, affected cell viability and proliferation. For concentrations between 0.5 and 2 mg/mL, the inhibition of cell proliferation was time-dependent, with slightly higher values corresponding to chemically synthesized HA when compared with hydrothermally synthesized HA. | [ |
| Nano-HA–silica-incorporated glass ionomer cement (HA–SiO2–GIC) | human Dental Pulp Stem Cells (DPSC) | MTT assay | HA–SiO2–GIC showed cytotoxic effects for all tested concentrations (3.125–200 mg/mL). | [ |
| HA coatings prepared by a sol–gel method on Ti6Al4V | human fetal osteoblasts, subcultures 4–6 | MTT assay | HA sol–gel-derived coatings | [ |
| HA nanoparticles (HA NPs) | Reconstructed human gingival epithelium (HGE) | MTT test; LDH assay | 3.1% HA NP solution did not induce cell death after 10 min, 1 h, and 3 h of incubation. | [ |
| HA composite with the mesoporous silicate MCM-48 | MG68 cells | MTT assay | MTT results showed the biocompatibility of the new material and supported its possible use as drug carrier. | [ |
| HA–Au nanoparticles | Human mesenchymal stem cells | MTS test; LDH assay | When compared with controls, the MTS assay showed no significant differences in the cell viability of cells exposed to 1–100 μg/mL HA–Au nanoparticles. LDH results indicated minimal damage to the cell membranes. | [ |
| High-temperature annealed nano-HA obtained via wet chemistry at 800 °C, 900 °C, and 1000 °C | L929 (NCTC clone 929) mouse fibroblast cells | MTT assay | All tested samples slightly decreased the viability of cells treated with 2.5, 5, 10, and 20 g/mL nanoparticle suspensions. | [ |
Figure 2Interactions of doped hydroxyapatite (HA) with several main biological processes, and their cellular outputs.
Investigation methods used to assess osteogenic effects. MSC—mesenchymal stem cell; ALP—alkaline phosphatase; BSP—bone sialoprotein; IFA—immunofluorescence assay; OCN—osteocalcin; CT—computed tomography; 3D—three-dimensional; CCK-8—Cell Counting Kit-8.
| Type of CaP | Biological Samples | Methodological Approach | Main Effects | References |
|---|---|---|---|---|
| Collagen/HA, | Rat MSCs | Cell proliferation (MTT) | Rapid increase of osteogenic marker gene expression; increased expression of ALP | [ |
| Sr-doped CaP | Human MSCs | Cell proliferation (LDH) | Increased proliferation; | [ |
| Collagen–nano-HA | Human MSCs | qRT-PCR | Increased osteogenic markers; mineral deposition | [ |
| Ag-doped hydroxyapatite/calcium silicate coating nano-Ti substrates | Mouse preosteobasts (MC3T3-E1 cells) | Cell proliferation (MTT) | Enhanced proliferation; | [ |
| Co2+- and Mg2+-doped HA | MG-63 osteoblasts | Flow cytometry | Similar cell-cycle profile as control cells; | [ |
| Biphasic calcium phosphate ceramics | Animal tissue | Histological analysis | Mineralized bone formation | [ |
| HA-coated implants | Animal tissue | Removal torque test | Higher removal torque value for HA group; | [ |
| HA-coated titanium implants | Animal tissue | Implant stability test | HA-favorable effect on osseointegration | [ |
| Ca-doped MgP, HA | Animal tissue | Histological analysis | Bone healing results with complete osseointegration | [ |
| Nano-to-submicron | MSCs | Cell count and morphology analysis | Reduced cell adhesion | [ |
| Sr-doped HA | MC3T3-E1 | Cell proliferation | Enhanced proliferation and ALP activity; | [ |
| Sr-doped HA | Animal tissue | Histological analysis | Higher regeneration efficacy of Sr-doped HA compared to HA and control | [ |
| Sr-doped HA | Animal tissue | Micro-CT assessment | Increased bone density around Sr-HA implants; improved trabecular | [ |
| Nanostructured HA scaffolds | Animal tissue | Histological analysis | Superior osteogenic capacity of foamed scaffolds compared to 3D-printed structures | [ |
| β-TCP scaffolds | MSCs | Cell proliferation (CCK-8), | Smaller pore sizes; improved bone regeneration | [ |
| Nano-HA | Animal tissue | Histological analysis | Bone regeneration similar to commercially available materials | [ |
| Nano-HA scaffolds | MSCs | Cell proliferation (MTT) | Nanostructured HA surfaces promote cell attachment, proliferation, and osteogenic differentiation; enhanced osteo- and angiogenesis in vivo | [ |
Investigation methods used to assess the angiogenic effects. HUVEC—human umbilical vein endothelial cells; IHC—immunohistochemistry; TCP—tricalcium phosphate; PU—polyurethane; PLGA/PCL—poly(lactic-co-glycolic acid)/poly(ε-caprolactone); HANW—HA nanowire; MS/CS—magnesium silicate core–shell; BMMSC—bone marrow-derived mesenchymal stem cells; CAM—chorioallantoic membrane; IF—immunofluorescence; VEGF—vascular endothelial growth factor; SCPP—Sr-doped calcium polyphosphate; n-ZnO—nano-zinc oxide; HIF-1α—hypoxia-inducible factor.
| Type of CaP | Biological Samples | Methodological Approach | Main Effects | References |
|---|---|---|---|---|
| Mg-doped HA | Co-culture model of HUVECs and MG63 | ELISA | Significant effects on bone formation and angiogenesis; | [ |
| - | IHC | Early angiogenesis followed by early osteogenesis | ||
| Bi-layered scaffold (type I collagen and Mg/HA) | hMSCs | IHC | Stimulating proliferation and differentiation of hMSCs for tissue growth and neo-angiogenesis | [ |
| 3D scaffold | - | IHC | Stimulating blood vessel formation | [ |
| HANW@MS/CS (Magnesium Silicate) | rBMMSCs | SEM | Mg and Si elements contribute to angiogenic induction, bone formation, and blood vessel formation | [ |
| Cu-doped HA | Animal tissue | IHC | CaP scaffold doped with low doses of copper sulfate led to the formation of micro-vessels | [ |
| Animal tissue | SEM | The micro/nano-structure of the Cu5–HA scaffold resulted in more angiogenesis, which formed the new blood vessels | [ | |
| Sr-doped CaP scaffold | Co-culture model of HUVEC and osteoblasts | Phase-contrast microscopy | Formation of tube-like structure and the expression of platelet endothelial cell adhesion molecule in co-cultured model was better in SCPP scaffold | [ |
| Animal tissue | IHC | New vessel formation in Matrix-50Sr-HA explants, mainly after 4 weeks of implantations, suggested a positive effect of Sr on angiogenesis | [ | |
| Co-doped HA | Animal tissue | IHC | Enhanced vascularization in vivo; large blood vessels were predominantly found in Co-doped HA | [ |
| Zn-doped HA | - | CAM assay | The number of vessel branches in the modified scaffolds with n-ZnO was significantly higher compared to the modified scaffolds without n-ZnO | [ |
| Li-doped HA | BMMSCs (bone-marrow mesenchymal stem cells) | Western blot analysis | HIF-1α and VEGF immunohistochemistry indicated that the hypoxia BMMSCs group had significantly more positive cells than the other three groups | [ |
Figure 3Cell signaling pathways activated in osteogenesis and angiogenesis models: Wingless-related integration site (Wnt) pathway, bone morphogenetic protein (BMP) pathway, and fibroblast growth factor (FGF)/platelet-derived growth factor (PDGF) pathway. Runt-related transcription factor 2 (RUNX2) is a major hub where all these pathways merge and cross-talk to guide the differentiation of bone and new vessels. Abbreviations: mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), osteocalcin (OCP), alkaline phosphatase (ALP), Osterix (Osx), BSP- Bone sialoprotein, BAP 1-BRCA1 associated protein-1, COL II- Collagen type II, SCUBE 3-Signal peptide-CUB-EGF-like domain-containing protein 3.